-- SCB-2019 (CpG 1018/Alum) elicited approximately 2-fold higher neutralizing antibody titers in adolescents (aged 12 to 17 years) compared to young adults (aged 18 to 25 years) --
-- Favorable tolerability and safety profile in adolescents, consistent with results previously observed in adults --
-- Clover plans to submit adolescent data to global regulatory authorities, in addition to its ongoing submissions for use in adults and elderly, to broaden potential use of SCB-2019 (CpG 1018/Alum) across age groups and as a universal COVID-19 booster vaccine --
https://finance.yahoo.com/news/clover-announces-positive-phase-2-102300251.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.